Related Experiment Video
Updated: Aug 16, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
[Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations]
J-C Corvol1, M Schüpbach, A-M Bonnet
1Centre d'Investigation Clinique et Fédération des Maladies du Système Nerveux, Hôpital de la Pitié-Salpêtrière, Paris. Jean-Christophe.corvol@psl.ap-hop-paris.fr
Introduction:
Pergolide is a widely used antiparkinsonian dopamine agonist. Following occasional case reports, two studies recently suggested potentially frequent and severe valvular disease associated with pergolide intake.
State Of Art:
Although there is now strong evidence to consider that pergolide may induce valvulopathy, incidence, severity, and risk factors for this adverse effect remain to be clarified. Valvular disease associated with pergolide consists in fibrosis and resembles conditions described in carcinoid carcinoma and in patients taking fenfluramine therapy. The mechanisms leading to valvular fibrosis are unknown but involvement of 5-HT(2B) receptors, especially expressed in valvular fibroblasts, is suspected.
Perspectives And Conclusions:
Following the recommendations of the Agence Française de Sécurité Sanitaire des Produits de Santé, we describe a clinical practice attitude for pergolide therapy in Parkinson's disease.
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse III: Nursing Management
Pericarditis III: Medical Management